Syed Suhaib Ahmed | Pharmacology | Young Scientist Award

Published on by Academic Excellence

Prof. Syed Suhaib Ahmed | Pharmacology | Young Scientist Award

Prof. Syed Suhaib Ahmed | Pharmacology | Yenepoya Universtiy | India

Dr. Syed Suhaib Ahmed, M.Pharm., Ph.D., is a dynamic academician and researcher specializing in pharmaceutics and nanomedicine. With a strong foundation in pharmacy, he has advanced his expertise through extensive teaching, research, and scholarly contributions. Currently serving as Assistant Professor at Yenepoya Pharmacy College & Research Centre, Mangalore, he also continues his impactful research journey initiated at JSS College of Pharmacy, Ooty. His Ph.D. project focused on the design and development of surface-conjugated solid lipid nanoparticles co-encapsulating a flavonoid and an anticancer drug for targeted colon cancer therapy. Dr. Ahmed has authored several national and international publications in reputed journals and presented his work at conferences and seminars. His innovative contributions to drug delivery systems, formulation development, and nanotechnology position him as a promising researcher in pharmacology. Recognized with fellowships and grants, Dr. Ahmed embodies academic excellence, research innovation, and a strong commitment to advancing pharmaceutical sciences.

Author Profiles

Orcid | Google Scholar

Education

Dr. Ahmed’s educational foundation reflects his dedication to pharmaceutical sciences. He completed his Bachelor of Pharmacy (B. Pharm.) in 2017 from Nalanda College of Pharmacy, Nalgonda, under JNTUH, securing a solid academic base. To advance his knowledge in drug formulation and delivery, he pursued M.Pharm. (Pharmaceutics) in 2019 at the same institution. His postgraduate research explored “Formulation and in vitro evaluation of doxophylline oral disintegrating tablets,” marking his early entry into formulation design. Driven by a passion for translational research, he enrolled for his Ph.D. (2022–2024) at JSS College of Pharmacy, Ooty, under JSS Academy of Higher Education & Research. His doctoral thesis centered on surface-conjugated solid lipid nanoparticles incorporating irinotecan and daidzein for colon cancer treatment, a study that combined advanced nanotechnology with oncology. This robust academic trajectory highlights his strong theoretical knowledge, practical research expertise, and innovation in pharmaceutics.

Experience

Dr. Ahmed has developed a rich blend of teaching and research experience that strengthens his academic profile. He began his career as a Lecturer at JSS College of Pharmacy, Ooty (Feb 2022 – July 2024), where he taught undergraduate and postgraduate pharmacy students while mentoring research projects. In September 2024, he joined Yenepoya Pharmacy College & Research Centre, Mangalore as an Assistant Professor, further expanding his teaching and mentoring contributions. Alongside academics, Dr. Ahmed has actively engaged in high-impact research, particularly in nanoparticle-based drug delivery systems. His doctoral project on colon-targeted lipid nanoparticles has provided novel insights into cancer therapeutics. Beyond teaching and research, he has attended 29+ conferences, delivered 9 presentations, and participated in 17 workshops, enhancing his professional network and exposure. His expertise in handling advanced instruments like DLS, DSC, XRD, and HPLC, combined with his strong teaching skills, showcases his versatility as both an educator and researcher.

Awards and Honors

Dr. Ahmed’s dedication to pharmaceutical research has been recognized through prestigious awards and fellowships. He was the recipient of the JSSAHER Fellowship, supporting his early-stage Ph.D. research on innovative nanoparticle drug delivery. Additionally, His academic excellence and contributions are further highlighted through multiple opportunities to present his work at national and international platforms. He has actively participated in over 29 conferences, 17 workshops, and 9 oral/poster presentations, gaining recognition for his innovative approaches in pharmaceutics. His scholarly publications in high-impact journals like the International Journal of Biological Macromolecules and Applied Organometallic Chemistry reflect his growing influence in the pharmacology community. These achievements stand as a testament to his perseverance, innovation, and leadership, positioning him as a rising figure in pharmaceutical sciences.

Research Focus

Dr. Ahmed’s research interests lie at the intersection of nanomedicine, targeted drug delivery, and formulation development. His Ph.D. research on solid lipid nanoparticles (SLNs) co-encapsulating irinotecan and daidzein represents a significant step forward in colon cancer therapy, addressing challenges of drug solubility, stability, and targeted delivery. By conjugating nanoparticles with hyaluronic acid and bovine serum albumin, he designed a system capable of actively targeting CD44 and SPARC receptors on colon epithelia, ensuring enhanced therapeutic efficacy. His research includes both in vitro assays on HT-29 colon cancer cells and in vivo studies in Wistar rats, demonstrating translational potential. Beyond oncology, he has contributed to fields like microneedle technology, nanoparticle synthesis, and orphan drug formulation challenges. He is also interested in QbD (Quality by Design) approaches, polymeric drug delivery systems, and risk assessment in pharmaceutical development. His work aims to bridge laboratory innovation with clinical applications, making a tangible impact in pharmacology.

Publications

  1. Oral delivery of SLNs decorated with hyaluronic acid and BSA: Novel colon cancer therapy – IJ of Biological Macromolecules, 2024.

  2. Green synthesis of BSA–silver nanoparticles with anticancer activity – Applied Organometallic Chemistry, 2024.

  3. Exploring multistage nanocarriers for colon cancer treatment – Journal of Research in Pharmacy, 2023.

  4. Challenges in developing generic orphan drugs: US & EU survey – Value in Health Regional Issues, 2023.

  5. Risk assessment in COVID-19 vaccine formulation and transfer – Vitae, 2022.

  6. Folic acid–tailored daidzein SLNs for cytotoxicity against colon cancer – IJ of Applied Pharmaceutics, 2024.

  7. Advancements in microneedle drug delivery systems – IJ of Applied Pharmaceutics, 2024.

  8. Molecular docking studies of benzylidene amino phenyl acetamides – IJ of Applied Pharmaceutics, 2024.

  9. Formulation & evaluation of doxophylline ODTs – Research Journal of Pharmacy and Technology, 2020.

  10. Pharmaceutical product life cycle challenges for generic approvals – Indian J of Pharmaceutical Education & Research, 2022.

Conclusion

Dr. Syed Suhaib Ahmed represents the new generation of pharmacology researchers, combining academic rigor with cutting-edge nanomedicine innovations. His scholarly contributions, teaching excellence, and impactful research on targeted cancer therapies demonstrate his potential to redefine future directions in pharmaceutical sciences. With strong recognition through fellowships, grants, and publications in reputed journals, he is poised to make lasting contributions to pharmacology and translational drug development.

Karthikeyan Kesavan | Pharmacology | Best Researcher Award

Published on by Academic Excellence

Assoc. Prof. Dr. Karthikeyan Kesavan | Pharmacology | Best Researcher Award

Assoc. Prof. Dr. Karthikeyan Kesavan | Pharmacology | Department of Pharmacy, Guru Ghasidas University | India

Dr. Karthikeyan Kesavan is an accomplished academic and researcher serving as an Associate Professor in the Department of Pharmacy at Guru Ghasidas Vishwavidyalaya, Bilaspur. With a Ph.D. in Pharmaceutics from IIT-BHU and postdoctoral research experience at the University of Iowa under the DBT-GETin Fellowship, he has established himself as an expert in nanopharmaceuticals and ocular drug delivery. His research integrates nanotechnology with pharmaceutics to design innovative formulations for treating complex ocular and infectious diseases. Dr. Kesavan has guided Ph.D. and postgraduate scholars, published extensively in high-impact journals, authored influential book chapters, and holds multiple patents in novel drug delivery technologies. His consultancy projects also extend expertise in nanoformulations of natural metabolites for managing ocular diseases. With an H-index of 16 and growing international collaborations, Dr. Kesavan continues to bridge cutting-edge research with practical healthcare applications, contributing significantly to the advancement of pharmacology and pharmaceutical sciences.

Author Profiles

Orcid | Google Scholar

Education 

Dr. Kesavan’s educational journey reflects excellence and dedication to pharmaceutical sciences. He earned his Bachelor of Pharmacy degree, which laid the foundation for his research interests, before pursuing a Master of Pharmacy (M. Pharm) in Pharmaceutics from Bharathidasan University. His academic passion led him to the prestigious Indian Institute of Technology (BHU), Varanasi, where he obtained his Ph.D. in Pharmaceutics, specializing in novel drug delivery systems. To further strengthen his expertise, he completed postdoctoral research at the University of Iowa, USA, under the distinguished DBT-GETin Fellowship, where he gained advanced experience in nanotechnology-based ocular drug delivery. This exposure enhanced his global outlook and scientific rigor, allowing him to integrate diverse approaches into his work. His education uniquely positioned him to contribute to both academic and industry-level pharmaceutical innovations. Today, his academic background continues to influence his impactful research in nanopharmaceuticals, ocular therapeutics, and gene delivery strategies.

Experience

Dr. Kesavan has more than a decade of experience in academia, research, and international collaboration. As an Associate Professor at Guru Ghasidas Vishwavidyalaya, he has played a pivotal role in advancing pharmaceutics education and research. His career includes mentoring doctoral and postgraduate students, designing advanced curricula, and fostering multidisciplinary projects. His consultancy experience extends to developing nanoformulations from medicinal plant metabolites for ocular disease management, bridging academia and applied science. Internationally, his postdoctoral research at the University of Iowa refined his expertise in nanocarrier-mediated gene therapy and non-viral delivery systems. Dr. Kesavan has completed projects funded by UGC, including innovative work on chitosan-coated cationic nanoemulsions for ocular delivery. His professional contributions encompass guiding clinical relevance, managing funded projects, publishing in SCI-indexed journals, authoring influential book chapters, and securing multiple patents. His diverse roles highlight his leadership in pharmacological innovation and his ability to translate research into practical applications.

Awards & Honors 

Throughout his career, Dr. Kesavan has earned significant recognition for his contributions to pharmaceutics and drug delivery research. His selection for the prestigious DBT-GETin Fellowship enabled him to conduct postdoctoral research at the University of Iowa, expanding his international collaborations. He has been awarded UGC-BSR startup grants for innovative work in ocular nanopharmaceuticals, particularly chitosan-coated cationic nanoemulsions. His impactful research has led to multiple patent awards, including recognition for hybrid hydrogel systems and IoT-based health monitoring devices, demonstrating his interdisciplinary innovation. Beyond patents, his publications in high-impact journals and contributions to specialized book chapters highlight his scientific leadership. His role in guiding research scholars and his consultancy services further showcase his dedication to advancing pharmaceutical sciences. These honors not only validate his scientific excellence but also underscore his commitment to pioneering new frontiers in pharmacology and translating research into therapeutic solutions.

Research Focus

Dr. Kesavan’s research focus lies at the intersection of nanotechnology and pharmacology, with a special emphasis on ocular drug delivery systems. His investigations aim to overcome biological barriers by developing innovative nanocarriers, such as nanoemulsions, micelles, and nanocapsules, for improved treatment of eye diseases like glaucoma, uveitis, bacterial keratitis, and fungal infections. His work also explores gene therapy approaches using non-viral vectors for safer and more effective management of ocular disorders. In addition, his patents reflect his expertise in designing mucoadhesive, biocompatible systems that enhance therapeutic efficacy while reducing side effects. Expanding beyond ocular pharmacology, he has also contributed to cancer therapy and infectious disease research through nanocarrier-based formulations. By integrating pharmaceutical sciences with biotechnology and engineering, Dr. Kesavan’s research demonstrates translational value, bridging laboratory discoveries with clinical applications. His focus continues to advance the field of nanopharmaceuticals, ensuring patient-centered, innovative, and sustainable therapeutic solutions.

Publications

    • Healing efficiency of nystatin-loaded chitosan-guar gum-based nanocapsules in experimental fungal keratitis.

    • Tear-Driven Phase Transition Microemulsion for Ocular Delivery of Dexamethasone in Uveitis.

    • Cationic microemulsion of voriconazole for fungal keratitis treatment: in vitro and in vivo evaluation.

    • TPGS-Chitosan Conjugated Mucoadhesive Micelles of Brinzolamide for Glaucoma Therapy.

    • Cationic Chitosan/Pectin Nanocapsules of Moxifloxacin for Bacterial Keratitis Management.

    • Cationic Polyelectrolyte Nanocapsules of Moxifloxacin for Microbial Keratitis Therapy.

    • Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy.

    • Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for glaucoma therapy.

    • Positively Charged TPGS-Chitosan Nanocapsules as Non-Viral Vector for Glaucoma Gene Therapy.

    • Topical Ocular Delivery of Nanocarriers: A Feasible Choice for Glaucoma Management.

    • Ocular SMEDDS of Prednisolone for Improved Uveitis Therapy .

    • Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy.

    • Phase Transition W/O Microemulsions for Antibacterial Activity in Bacterial Keratitis.

    • Chitosan-Coated Microemulsions for Enhanced Dermal Clotrimazole Delivery.

Conclusion

Dr. Karthikeyan Kesavan exemplifies excellence in pharmacology through his pioneering research in nanopharmaceuticals, ocular drug delivery, and innovative therapeutic approaches. With a strong educational foundation, impactful teaching experience, and international collaborations, he has established himself as a leader in pharmaceutical research. His extensive publications, patents, and consultancy work highlight his contributions to both academic and industrial advancements. Dr. Kesavan’s dedication to addressing unmet medical needs through nanotechnology-driven solutions continues to shape the future of pharmacology, making him a highly deserving candidate for recognition in the field.